Ionis/Roche's Huntington's Drug 'Next Spinraza'?
Further details of a Phase I/II study results are raising hopes that it could be the first disease-modifying treatment for the disease, but it is not yet known whether the reduction in Huntintin seen will translate into a clinical benefit.
You may also be interested in...
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.